Reinventing MS therapy. Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint accelerator of the University of Zurich and ETH Zurich. The phase I trial showed excellent tolerability and safety and indicated the induction of several tolerance mechanisms.
| Website | http://www.cellerys.com |
| Employees | 11 (8 on RocketReach) |
| Founded | 2015 |
| Address | Wagistrasse 21, Schlieren, Zurich 8952, CH |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Multiple Sclerosis Treatment, Therapeutic Solutions, Ms Research, Neurological Drug Development, Neurological Disease Treatment, Pharmaceutical Research, Central Nervous System, Clinical Trials, Autoimmune Disease Treatment, Biotechnology, Innovative Therapies, Drug Discovery, Precision Medicine, Phase 1 Trials, Regenerative Medicine, Health Technology, Biomedical Research, Pharmaceutical, Life Sciences |
| Competitors | Zymeworks Inc., Celerion, AstraZeneca, Thermo Fisher Scientific, abcam, Lonza, MilliporeSigma, Cell Signaling Technology (CST), Bio-Rad Laboratories, Bio-Techne +45 more (view full list) |
Looking for a particular Cellerys AG employee's phone or email?
Roland Martin is the Chief Scientific Officer of Cellerys AG.
8 people are employed at Cellerys AG.
Cellerys AG is based in Schlieren, Zurich.